ArticleJournal of medicinal chemistry2009
Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase.
Article in Journal of medicinal chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 69 citations in OpenAlex.
- Kinetic and Structural Characterization ofBiochemistry · 2023Article
- Kinetic Characterization and Inhibition ofBiochemistry · 2022Article
- Nucleoside Hydrolase NH 36: A Vital Enzyme for theFrontiers in immunology · 2019Review
- Enzymatic Transition States and Drug Design.Chemical reviews · 2018Review
- Intracellular rebinding of transition-state analogues provides extendedThe Journal of biological chemistry · 2017Article
- Oligonucleotide transition state analogues of saporin L3.European journal of medicinal chemistry · 2017Article
- Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis.PLoS neglected tropical diseases · 2015Article
- New Antibiotic Candidates against Helicobacter pylori.Journal of the American Chemical Society · 2015Article
- Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines.Bioorganic & medicinal chemistry · 2015Article
- Mannich bases in medicinal chemistry and drug design.European journal of medicinal chemistry · 2015Review
- Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro.PloS one · 2015Article
- New function for Escherichia coli xanthosine phophorylase (xapA): genetic and biochemical evidences on its participation in NAD(+) salvage from nicotinamide.BMC microbiology · 2014Article
- Gold(I) complexes of 9-deazahypoxanthine as selective antitumor and anti-inflammatory agents.PloS one · 2014Article
- Guanosine negatively modulates the gastric motor function in mouse.Purinergic signalling · 2013Article
- Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases.The Journal of biological chemistry · 2013Article
- Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.Bioorganic & medicinal chemistry · 2013Article
- Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria.Future medicinal chemistry · 2013Review
- Transition state analogue inhibitors of human methylthioadenosine phosphorylase and bacterial methylthioadenosine/S-adenosylhomocysteine nucleosidase incorporating acyclic ribooxacarbenium ion mimics.Bioorganic & medicinal chemistry · 2012Article
- [(3R*,4R*,5R*)-2,3-Diphenyl-isoxazolidine-4,5-di-yl]dimethanol.Acta crystallographica. Section E, Structure reports online · 2012Article
- Acyclic immucillin phosphonates: second-generation inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.Chemistry & biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
ImmH (1) and DADMe-ImmH (2) are potent inhibitors of human purine nucleoside phoshorylase (PNP), developed by us and currently in clinical trials for the treatment of a variety of T-cell related diseases. Compounds 1 and 2 were used as templates for the design and synthesis of a series of acyclic immucillin analogues (8-38) in order to identify simplified alternatives to 1 and 2. SerMe-ImmG (8) and DATMe-ImmG (9) displayed the lowest inhibition constants of 2.1 and 3.4 pM, respectively, vs PNP. It was postulated that the flexible natures of 8 and 9 enabled them to adopt conformations resembling those of 1 and 2 within the active site of PNP and that the positioning of two hydroxyl groups was critical for picomolar activity. SerMe-ImmH (10, K(d) = 5.2 pM) was shown to be orally available in mice with a long biological residence time on blood PNP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.